I-Seelos Therapeutics, Inc., inkampani yekliniki ye-biopharmaceutical egxile ekuphuhliseni unyango lweengxaki zenkqubo ye-nervous kunye nezifo ezinqabileyo, namhlanje ibhengeze ukuba ifumene ileta yokuvuma iSaziso se-Clinical Trial Notification (CTN) evela kwiSebe lezeMpilo lase-Australia. Ulawulo lweeMpahla zeTherapeutic (TGA) kwisifundo somqhubi we-SLS-005 (i-injection ye-trehalose, i-90.5 mg / mL ye-intravenous infusion) yonyango lwezigulane ezine-Alzheimer's disease.
“Umsebenzi we-Trehalose kwisifo i-Alzheimer wahlukile njengoko unqanda zombini i-beta-amyloid pathology kunye ne-tau aggregates kwiimodeli zeempuku zangaphambili. Lo msebenzi ubonakala ungaphakathi kwe-intraneuronal, eyenzeka ngaphakathi kwiseli, eyahlukileyo kwiindlela zonyango ezijoliswe kwi-antibody. Zombini i-amyloid precursor protein kunye ne-tau oligomers zi-cytoplasmic ngaphakathi kweseli kwaye zinokwenziwa yi-Trehalose ngokubangela i-autophagy kunye ne-proteasomal systems. I-Autophagy iye yabandakanyeka ekuthotyweni kwezinye iiprotheyini ezidityanisiweyo, "utshilo uRaj Mehra Ph.D., uSihlalo kunye ne-CEO yeSeelos. "Silindele ukufumana ubungqina kunye nokuqonda okubalulekileyo malunga nokufaneleka kwe-SLS-005 kunyango lwezi meko ze-neurological, eziphazamisa kakhulu emzimbeni, ngokweemvakalelo nangokwezemali kwizigulana kunye neentsapho zabo."
Ukongeza, uSeelos wafumana isigunyaziso sokuqhuba isifundo sebhaskithi esivulekileyo (ACTRN: 12621001755820) e-Australia ukuvavanya ukusebenza kwe-SLS-005 ekuqhubekeni kwesifo kunye nobukhulu, kunye nokhuseleko kunye nokunyamezela, kubathathi-nxaxheba abanezifo ezikhethiweyo ze-neurodeergenerative. kuquka nesifo sikaHuntington.
Umbutho olawulayo wase-Australia kulingo lwezonyango, i-TGA, kunye neNkuthazo yeRhafu yoPhando kunye noPhuhliso lukaRhulumente wase-Australia inika ithuba elinomtsalane kakhulu kwiinkampani ezincinci zebhayoloji zase-US ukuba ziqalise ulingo lwezonyango e-Australia ngeenzame zokukhawulezisa ukuqaliswa kwezifundo kunye nokusebenzisa ikliniki eyomeleleyo yelizwe. izakhono zovavanyo.
